Therefore, an AAV mediated CRISPR-Cas approach could be employed to target the aberrant TCF4. Lastly, in FECD treated with corneal grafting, gene therapy to prevent corneal graft rejection, as discussed in Section 6.7, or gene therapy to reduce fibrosis may improve treatment outcomes and vision [82]. This evidence concerns the gene TCF4 and Fuchs' endothelial dystrophy.